Monty Pal, MD, FASCO, presents a case of a 71-year-old patient with relapsed-refractory mRCC and discusses his data-informed rationale for treatment selection and sequencing in the treatment landscape of metastatic renal cell carcinoma.
EP. 1: A 71-Year-Old Woman with Relapsed-Refractory (R/R) Metastatic Clear Cell Renal Cell Carcinoma
Monty Pal, MD, introduces a metastatic clear cell renal cell carcinoma (ccRCC) patient case and shares how he may approach treatment.
EP. 2: Factors Influencing Treatment Selection and Sequencing in Advanced Renal Cell Carcinoma
Dr. Pal discusses clinical insights concerning treatment selection and sequencing in patients with metastatic renal cell carcinoma.
EP. 3: Data-Informed Discussion of Tivozanib in Patients with Metastatic Renal Cell Carcinoma
Thoughtful discussion of study data supporting the use of tivozanib in patients with metastatic renal cell carcinoma, in the relapsed/refractory setting.
EP. 4: Utilizing Lenvatinib Plus Everolimus in the Metastatic Renal Cell Carcinoma Setting
A closer look at lenvatinib plus everolimus in patients with advanced renal cell carcinoma, touching on dose-related toxicities.
EP. 5: The Evolving Renal Cell Carcinoma Treatment Landscape: 2023 and Beyond
Monty Pal, MD discusses the implications of updated NCCN guidelines on mRCC treatment selection and sequencing in 2023 as well as unmet needs in the mRCC treatment landscape.
2 Clarke Drive Cranbury, NJ 08512